HER3 is a re-emerging target that has been implicated in playing a role in treatment resistance as well as poor outcomes for patients with NSCLC. Antibody-drug conjugates (ADCs) offer a novel approach to targeting HER3 as a method of delivering a cytotoxic payload that eliminates tumor cells. Learn about ongoing clinical trials are evaluating a HER3-targeted ADC for NSCLC to offer an additional treatment option.
HER3
The HOPE for NSCLC Learning Center is an educational resource developed by Paradigm Medical Communications in collaboration with The American Lung Association. The Learning Center, which features multiple individually accredited CME activities and patient and clinician resources, is for educational purposes only. Healthcare professionals are expected to employ their own knowledge and judgement during any discussion with, or treatment of, their patients.
For questions or technical support please email us at contactus@paradigmmc.com.